

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
3 March 2005 (03.03.2005)

PCT

(10) International Publication Number  
**WO 2005/018494 A1**

(51) International Patent Classification<sup>7</sup>: **A61F 2/00**

(21) International Application Number:  
PCT/US2003/025452

(22) International Filing Date: 14 August 2003 (14.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant: **BOSTON SCIENTIFIC LIMITED** [IE/IE];  
The Corporate Center, Bush Hill, Bay Street, St. Michel  
(BB).

(72) Inventor: **CHU, Michael, S., H.**; 121 Browne Street,  
Brookline, MA 02446 (US).

(74) Agents: **LEE, Agnes, S. et al.**; Ropes & Gray LLP, One  
International Place, Boston, MA 02110-2624 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **MEDICAL SLINGS**



(57) Abstract: The invention involves a medical sling, which maintains its shape during placement, and related method. In one embodiment, the invention features a sling having a first portion, a second portion and an intermediate portion, located longitudinally between the first and second portions. The sling further includes a first elongated member extending longitudinally along the first portion and a second elongated member extending longitudinally along the second portion; and the first and second elongated members being separated by the intermediate portion of the sling.

## MEDICAL SLING

Technical Field

5           This invention generally relates to treating or reinforcing a damaged, prolapsed, weakened or herniated portion of a patient's body with a sling.

Background of the Invention

          Conditions such as rectocele, cystocele, enterocele, vaginal prolapse, and protocele involve tissues or organs that have been damaged, prolapsed, weakened, or otherwise herniated.

10   A prolapse refers to the slipping of an organ, or organ part, from its normal position. For example, a prolapse of the rectum refers to the protrusion of the rectum through the anus. Rectocele is the prolapse of the rectum into the perineum. A prolapse of the uterus refers to the falling of the uterus into the vagina due to stretching and laxity of its supporting structures. Vaginal vault prolapse refers to the prolapse of the cephalad extreme of the vaginal wall toward, through, and beyond the introitus. Cystocele (i.e., vesicocoele) is a hernia formed by the  
15   downward and backward displacement of the urinary bladder toward the vaginal orifice, due most commonly to weakening of the musculature during childbirth. However, any abnormal descent of the anterior vaginal wall and bladder base at rest or with strain is considered cystocele. Enterocele is a hernia of the intestine, though the term is also used to refer  
20   specifically to herniation of the pelvic peritoneum through the rectouterine pouch (i.e., posterior vaginal, rectovaginal, cul-de-sac, or Douglas' pouch hernia). Proctocele is a prolapse of the mucous coat of the rectum due mostly from relaxation of the sphincter. Treatment of these conditions frequently requires a sling, such as a mesh sling, implanted at the anatomical site-requiring repair.

25           Stress urinary incontinence (SUI) primarily affects women and generally is caused by two conditions that may occur independently or in combination, namely, intrinsic sphincter deficiency (ISD) and hypermobility. In ISD, the urinary sphincter valve, located within the urethra, fails to close properly, causing urine to leak out of the urethra during stressful actions. Hypermobility is a condition in which the pelvic floor is distended, weakened, or damaged,  
30   causing the bladder neck and proximal urethra to rotate and descend in response to increases in intra-abdominal pressure (e.g., due to sneezing, coughing, straining, etc.), resulting in

5 insufficient response time to promote urethral closure and, consequently, in urine leakage and/or flow.

Biological factors that may affect hypermobility include: poor endopelvic fascia muscle tone (from, for example, age or limited activity), endopelvic fascia muscle stretch/tear from trauma (e.g., childbirth), endopelvic fascia/arcus tendinous (muscle/ligament) separation (lateral  
10 defect), hormone (e.g., estrogen) deficiency, concomitant defects (e.g., cystocele, enterocele, and ureteral prolapse), and vaginal prolapse. Traditional treatment methods include urethra or bladder neck stabilization slings in which a sling is placed under the mid-urethra or bladder neck to provide a platform preventing over distention.

Slings are traditionally placed under the urethra or bladder neck to provide a urethral  
15 platform limiting endopelvic fascia drop while providing compression to the urethral sphincter to improve coaptation. The urethral placement location provides mechanical stability to a less moveable anatomical structure. Bladder neck slings traditionally have been affixed in the desired location using a bone anchoring method. Mid-urethral slings, being placed in a low mobility area, may be placed using an anchorless approach. Recognizing that minimal tension, if  
20 any, is necessary, a physician may need only to secure a mid-urethra sling through the endopelvic fascia. The sling in this placement provides a fulcrum about which the pelvic floor will drop (taking advantage of the hypermobility condition of the patient) and a urethral "kink" or higher resistance to obstruct urine flow during high stress conditions.

A problem associated with sling placement is that a sling often loses its desired shape  
25 during the handling of the sling as it is implanted in a patient's body. This is due to the tension and other forces that are applied to the sling during the implantation procedure. As a result of the forces, the sling can become stretched and narrowed and may no longer be able to anchor properly in the body. This improper anchoring can result in the sling providing only poor support, leading to a failed surgical procedure.

### 30 Summary of the Invention

The invention, in one embodiment, addresses the deficiencies of the prior art, by providing a medical sling that maintains its shape during placement, and related methods. In one aspect, the invention features a sling including an elongated member extending longitudinally along a portion of the sling's length. This elongated member inhibits at least a portion of the

5 sling from stretching longitudinally, and thus, controls and maintains the width of the sling. In another embodiment, the invention features a sling where one or more of its sides is structurally strengthened, for example, by detangling. The detangled side reinforces the structure of the sling and limits the sling from stretching longitudinally.

10 In one aspect, the invention features a sling having a first portion, a second portion and an intermediate portion, located longitudinally between the first and second portions. A first elongated member extending longitudinally along the first portion and a second elongated member extending longitudinally along the second portion; and the first and second elongated members being separated by the intermediate portion of the sling. In one embodiment, the first and second elongated members are formed from a substantially rigid material. The intermediate  
15 portion can be of any length, e.g., the intermediate portion is between, e.g., 1 cm to 15 cm in length or 1 cm to 7 cm in length.

In another embodiment, the sling further includes a tensioning-device device located in the intermediate portion of the sling. The tensioning device can include a looped thread. The looped thread can be attached to the first elongated member, the second elongated member or  
20 both elongated members. Optionally, the tensioning device is only secured to the intermediate portion of the sling, but does not attach to the first or second elongate members. In another configuration, the thread secures to the sling material in a zigzag configuration.

In another embodiment, the tensioning device includes a handle for positioning the sling in a patient's body.

25 The sling can be made of various materials. In one embodiment, the sling can be made from a perforated material. In another embodiment, the sling can be made from a non-perforated material. In still yet another embodiment, the sling is a mesh. Other materials include, for example, a synthetic material, a mammalian tissue, or a combination of a synthetic material and a mammalian tissue. The sling can be of any shape suitable for its application. In a preferred  
30 configuration, the sling has a substantially rectangular shape.

In another aspect, the invention features a sling having a first edge that is structurally strengthened to increase sling rigidity. In one embodiment, the sling includes a second, structurally strengthened edge disposed opposite and away from the first edge. In another embodiment, the first edge and the second edge are detangled. According to some

5 configurations, the sling has an irregular surface. Such irregularity may include, for example, the surface ridges, projections, depressions or combinations thereof or the like.

In another aspect, the invention features a method of making a sling for implantation at an anatomical site in a patient. The method includes securing to the sling a first elongated member extending longitudinally along a first portion of the sling; securing to the sling a second  
10 elongated member extending longitudinally along a second portion of the sling, the first and second portions being separated by an intermediate portion. In one embodiment, the first and second elongated members are made of a substantially rigid material. In another embodiment, the intermediate portion is about 1 cm to about 15 cm in length, for example, between about 1 cm to about 7 cm in length. In one embodiment, the method can further include securing a  
15 tensioning device such as a looped thread to the intermediate portion of the sling.

In another aspect, the method of the invention includes providing a sling with first and second edges and treating at least one of the edges to increase structural rigidity. The treating can include smoothing such as heating at least one of the edges. The melting can be performed with a heating element. In one embodiment, at least one of the edges includes tangs projecting  
20 therefrom and heating includes smoothing the at least one edge to substantially remove the tangs. The method further includes smoothing tangs projecting from the first edge and the second edge.

The sling can be made of various materials. In one embodiment, the sling can be made from a perforated material. In another embodiment, the sling can be made from a non-perforated material. In still yet another embodiment, the sling is a mesh. Other materials include, for  
25 example, a synthetic material, a mammalian tissue, or a combination of a synthetic material and a mammalian tissue. The sling can be of any shape suitable for its application. In a preferred configuration, the sling has a substantially rectangular shape.

In another embodiment, the invention features a method of delivering a sling to the periurethral tissues of the patient. The method includes providing a sling as described above and  
30 delivering the sling to the periurethral tissues of the patient. The method can be used, for example, to deliver a sling to a site in the body of a patient using a transvaginal, transabdominal (e.g., supra-or pre-pubic) or transobturator approach.

5

Brief Description of the Drawings

In the drawings, like reference characters generally refer to the same or similar parts throughout the different views. The drawings are not necessarily to scale, but rather illustrate the principles of the invention.

FIG. 1 depicts a top view of a sling including an elongated member for inhibiting  
10 longitudinal stretching according to an illustrative embodiment of the invention.

FIG. 2 depicts a cross-sectional view of a sling including an elongated member on a first surface according to an illustrative embodiment the invention.

FIG. 3 depicts a cross-sectional view of a sling including an elongated member running through at least a portion of its length according to another illustrative embodiment the  
15 invention.

FIG. 4 depicts a top view of a sling including a plurality elongated members for inhibiting longitudinal stretching according to another illustrative embodiment of the invention.

FIG. 5 depicts a top view of a sling including a tensioning device according to an illustrative embodiment of the invention.

20 FIG. 6 depicts a top view of a sling including a tensioning device according to another illustrative embodiment of the invention.

FIG. 7 depicts a top view of a sling having one reinforced edge according to an illustrative embodiment of the invention.

Illustrative Description of the Invention

25 In general, the invention provides a sling that overcomes many of the limitations of the slings in the prior art, which typically become misshapen during surgical placement and do not anchor properly in tissues. According to one feature, the sling of the invention has an elongated member that is attached and parallels the longitudinal axis of the sling. In addition, the sling has an intermediate portion that is free of an elongated member. The elongated member controls the  
30 longitudinal stretching of the portion of the sling to which it is attached. The elongated member thereby inhibits the portion of the sling to which it is attached from narrowing when the ends of the sling are pulled in opposite directions.

According to another feature, the sling of the invention is structurally strengthened. The structural reinforcement limits stretching and helps the sling maintain its shape.

5           FIG. 1 depicts a top view of a sling 20 including first 28a and second 28b elongated members according to illustrative embodiment of the invention. The illustrative elongated members 28a and 28b parallel the longitudinal axis 21 of the sling 20. The sling 20 also includes first 24 and second 26 sides, first 10 and second 12 edges, and first 60 and second 62 ends. In the illustrative embodiment, the elongated members 28a and 28b are substantially rectangular and substantially flat. However, in alternative illustrative embodiments, the elongated members 28a and 28b may be suture-like.

          As shown in FIG. 1, the first elongated member 28a has first 44 and second 40 terminal ends. Similarly, the second elongated member 28b has first 46 and second 42 terminal ends. Other embodiments may have more than two elongated members, for example, three, four, or  
15   five elongated members. The first elongated member 28a secures, for example, at the first end 44 to the first end 23 of the sling and longitudinally extends along a first sling portion 25. The second elongated member 28b secures, for example, at its first end 46 to the second end 62 of the sling 20 and extends longitudinally along a second sling portion 27. The first 28a and second 28b elongated members secure to the sling 20 such that the second end 40 of the first elongated  
20   member 28a and the second end 42 of the second elongated member 28b are non-overlapping.

          According to this configuration, an intermediate portion 36 of the sling 20 does not include any portion of the elongated members 28a and 28b. In one particular clinical application of the illustrative embodiment of FIG. 1, the elongated member-free intermediate portion 36 of the sling 20 is implanted in close proximity to the patient's tissue in need of repair. For example,  
25   the elongated member-free intermediate portion 36 of the sling 20 may be positioned under the patient's urethra for the treatment of urinary incontinence. For this illustrative clinical application, the length of the intermediate portion 36 is preferably in a range of about 1 to about 20 cm, about 2 to about 15 cm, about 3 to about 10 cm, or about 4 to about 5 cm. So configured, the intermediate portion 36 of the sling 20 is more longitudinally expandable than the portions of  
30   the sling 20 that have an attached elongated member 28a or 28b. In other words, the size and shape of the portions of the sling 20 having an attached elongated member 28a or 28b is less changeable in its long axis in comparison to the intermediate portion 36 of the sling 20, which can expand and contract more freely along at least the longitudinal axis 21.

5           In one illustrative embodiment, the thickness of the sling 20, i.e., the thickness between the first side 24 and the second 26, is substantially uniform over the entire sling 20. Alternatively, the thickness varies at one or more different locations on the sling 20. In the case where the sling 20 is formed from a mesh material, thickness of the mesh may be considered, without the taking into account the holes in the mesh. The thickness of the sling 20 ranges, for  
10           example, from about 0.02 to about 0.10 cm, preferably, about 0.07 cm. The sling 20 is preferably in the range of about 20 to 50 cm in length, and about 1 to about 3 cm wide. However, the sling 20 is not limited to the size disclosed as larger or smaller slings 20 may be employed to suit various applications and the size of the patient.

          According to one feature, the sling 20 is substantially rectangular in shape from a top  
15           view. In other embodiments, the sling 20 may have a trapezoidal, hexagonal, octagonal or elliptical top view shape, or any suitable shape for its intended location at an anatomical site within a patient's body. According to another feature, the sling 20 includes tangs (e.g., projections) that extend laterally from the edges 10 and 12.

          The illustrative elongated members 28a and 28b secure to the sling 20, for example, by  
20           molding, gluing, bonding or weaving the elongated members 28a and 28b to the material of the sling 20, or by otherwise physically or chemically securing the elongated members 28a and 28b to the sling 20.

          FIG. 2 depicts a cross sectional view along the line AA of the illustrative sling 20 of  
FIG. 1. As shown, the elongated member 28a of FIG. 2 attaches to the side 24 of the sling 20.  
25           The elongated member 28b attaches in a similar fashion. In alternative embodiments, the elongated member 28a and/or 28b may alternatively or additionally attach to the side.

          FIG. 3 depicts a cross-sectional view along the line AA of a sling 20 according to an  
alternative illustrative embodiment of the invention. In this illustrative embodiment, the  
elongated members 28a and/or 28b are embedded or interwoven into the sling 20, for example,  
30           between the first side 24 and second side 26.

          FIG. 4 depicts a top view of an alternative illustrative embodiment of the sling 20  
employing four elongated members 28a-28d. In place of the single portion elongated member  
28a traversing the sling 25, the embodiment of FIG. 4 provides two elongated members 28a and  
28c spaced apart from each other and the edges 10 and 12, and spaced symmetrically about the  
35           central longitudinal axis 21. The two elongated members 28b and 28d are similarly spaced along



5 the sling portion 27. As in the embodiment of FIG. 1, an intermediate portion 36 of the sling 20 is configured to be elongated member-free. Preferably, the elongated members 28a-28d are configured to be small enough so as not to substantially inhibit tissue ingrowth into the sling 20 when the sling 20 is implanted in the body of a patient.

FIG. 5 depicts a top view of an alternative embodiment of the invention in which the  
10 sling 20 includes a tensioning device 38. The tensioning-device 38 limits the tension applied to the intermediate portion 36 of the sling 20. The tensioning device 38 also aids in maintaining the size and shape of the intermediate portion 36 of sling 20 during surgical placement of the sling 20 in the patient's body.

As depicted in FIG. 5, the tensioning device 38 is, for example, a suture looped to at least  
15 partially circumscribe the intermediate portion 36 of sling 20. Illustratively, the tensioning device 38 secures to the second end 40 of the first member 28a and to the second end 42 of the second member 28b. The length of the tensioning device 38 limits the length of available stretch in the intermediate portion 36 of the sling 20 when the sling 20 is pulled along its longitudinal axis 21. Preferably, the length of the tensioning device 38 is selected to prevent the intermediate  
20 portion 36 of the sling 20 from exceeding a length beyond which its elasticity is insufficient to enable it to return to its original length. According to another feature, the tensioning device 38 terminates in an end 56 configured to be used as a positioner to position the sling 20 during placement in the body of a patient. Although the end 56 is illustratively depicted as intertwined suture ends, it may have any suitable configuration such as, for example, a tab or handle.

FIG. 6 depicts a top view in another alternative embodiment of the invention in which the  
25 tensioning device 38 of the sling 20 is configured as a zigzag stitch longitudinally extending along the intermediate portion 36. In this embodiment, the tensioning device, preferably, is not attached to either elongated member 28a or elongated member 28b. However, in alternative embodiments, the terminal ends 43 and 45 of the tensioning device 38 may attach to the ends 43  
30 and 45, respectively, of the elongated elements 28a and 28b. The sling 20 may be tensed by pulling on the ends 60 and 62 of the sling 20. The amount of longitudinal expansion of the intermediate portion 36 is determined by the number length and width of the zigzag stitches.

The illustrative tensioning-device 38 of FIGS 5 and 6 may be made from, for example, resorbable or non-resorbable suture material or thread. For example, a resorbable suture material  
35 such as PLA (poly lactic acid), PGA (poly glycolic acid), PLLA (poly-L-lactic acid), or other

5 resorbable polymers may be employed. Alternatively, non-resorbable materials, such as polypropylene (PP), polybutester or other non-resorbable polymers may be employed. According to one feature, the tensioning-device 38 is embedded into the sling 20 by, for example, weaving, molding or bonding it to the sling 20, or by otherwise physically or chemically attaching the it to the sling 20.

10 FIG. 7 is a top view of the sling 20 structurally reinforced at edge 10 but not at edge 12. Tangs (i.e., sharp projections or frayed edges) can form, for example, in the edges 10 and 12 and/or in the ends 60 and 62, when the sling material is cut, chopped, torn, frayed or otherwise manufactured. As depicted in FIG. 7, the edge 10 is smoothed to remove any such tangs and to structurally strengthen the sling 20. Any process for smoothing the edges 10 and 12 may be  
15 used. For example, the edge 10 may be heat smoothed by burning or melting. In the detangling method, the fiber ends (tang) of the mesh are melted to a point on the mesh where the fibers cross. The melted fiber ends combine and are locked together at the intersection. Such a detangling method not only smooths the edge 10, but also structurally stiffens it. The sling edge 12, and ends 60 and 62, may be similarly smoothed and stiffened.

20 An exemplary method of making a sling 20 having detanged sides 10 and 12, for example, includes manufacturing a sling material having tangs on at least side 10 or 12. The tangd sides 10 and/or 12 are then smoothed by exposing the side(s) 10 and/or 12 to a source of heat (i.e., by contact or by bringing the heat source into close proximity to the side(s) 10 and/or 12). In an alternative method, a straight blade edge that is heated to a sufficient temperature is  
25 employed simultaneously cut and smooth the side(s) 10 and/or 12.

The slings described above can be used, for example, in the treatment of urinary incontinence, and may terminate in any suitable configuration or structure such as loops, apertures, male and female connectors, guide tubes and the like. Exemplary configurations and structures are disclosed in U.S. provisional patent application serial No. 60/403,555, U.S. patent  
30 application serial No. 10/325,125, U.S. provisional patent application serial No. 60/418,827, U.S. provisional patent application serial No. 60/418,642, and U.S. provisional patent application serial No. 60/434,167, the entire contents of which are incorporated herein by reference.

In another aspect, the slings of the invention may be employed with any suitable delivery systems. Such delivery systems include, for example, those delivery systems configured for

5 supra-pubic, pre-pubic, transvaginal or transobturator approaches. Without limitation, delivery systems and methodologies that may be employed in combination with the slings of the invention can be found, for example, in U.S. patent application serial No. 10/093,498, U.S. patent application serial No. 10/093,398, U.S. patent application serial No. 10/093,450, U.S. patent application serial No. 10/094,371, U.S. patent application serial No. 10/094,352, U.S. patent application serial No. 10/093,424, U.S. provisional patent application serial No. 60/403,555, U.S. provisional patent application serial No. 60/418,827, U.S. provisional patent application serial No. 60/418,642, U.S. provisional patent application serial No. 60/274,843, U.S. provisional patent application serial No. 60/286,863 and U.S. provisional patent application serial No. 60/434,167, the entire contents are incorporated herein by reference.

15 As mentioned above, the slings of the invention may have any suitable size or shape configuration and may include any complimentary features. In a particular embodiment, the sling includes a protective sleeve (not shown), which encloses the sling during delivery into the patient's body. Without limitation, various applicable sling configurations are disclosed in U.S. patent application serial No. 09/916,983, U.S. patent application serial No. 10/093,498, U.S. provisional patent application serial No. 60/465,722, U.S. patent application serial No. 10/092,872, U.S. patent application serial No. 09/916,983, U.S. provisional patent application serial No. 60/449,465, U.S. provisional patent application entitled Surgical Slings, to Li et al, Attorney Document No.: BSC-279PR, filed on even day herewith, U.S. patent application entitled Systems, Methods and Devices relating to Delivery of Medical Implants, to Chu et al., Attorney Document No.: BSC-267-1; BSC-267-2; BSC-267-3; and BSC-267-4, filed on even day herewith, U.S. patent application entitled Medical Implant, to Chu et al., Attorney Document No.: BSC-255, filed on even day herewith, and U.S. patent application entitled Medical Slings, to Rao et al, Attorney Document No.: BSC-265, filed on even day herewith, the entirety of the disclosures of which are incorporated by reference herein.

30 In one illustrative embodiment, the sling 20 may be formed from imperforate or perforated materials. Also, the sling 20 may include a foam material. The foam material can be disposed, for example, into an interior hole or holes in the sling or otherwise embedded into the sling 20, or disposed onto one or more surfaces, sides or edges of the sling 20. The foam material can be adhered to the sling 20 by thermal bonding. The foam material can also be configured to efficiently absorb a drug or therapeutic agent prior to implantation and to release

35

5 the therapeutic agent at a desired rate in the body, providing, for example, extended release. Exemplary therapeutic agent includes neomycin, sulfa drugs, antimicrobials, and antibiotics. Other exemplary therapeutic agents are described below. The foam material may be manufactured from, for example, polyvinyl acetate (PVA), polyurethane, silicone, polyester, polyethylene, etc.

10 The elongated members 28a, 28b, 28c and/or 28d of the invention can be made from the same materials as the sling 20 as described below. In a particular embodiment, the elongated members 28a-28d are made from materials that are more rigid than the materials used to make the sling 20. The elongated members 28a-28d may be made, for example, from resorbable or non-resorbable suture material or thread. Resorbable suture materials such as PLA (poly lactic  
15 acid), PGA (poly glycolic acid), PLLA (poly-L-lactic acid), or other resorbable polymers may be employed. Non-resorbable materials such as polypropylene (PP), polybutester or other non-resorbable polymers may be employed.

The sling 20 may be fabricated from any of a number of biocompatible materials such as nylon, polyethylene, polyester, polypropylene, fluoropolymers, copolymers thereof,  
20 combinations thereof, or other suitable synthetic material(s). The sling 20 may be, for example, a synthetic material that is absorbable by the patient's body. Suitable absorbable synthetic materials include polyglycolic acid (PGA), polylactic acid, and other suitable absorbable synthetic materials. A suitable PGA material is available under the trade designation DEXON, from TYCO (Exeter, NH). Other suitable polymeric, non-polymeric synthetic materials or their  
25 combination may be employed in accordance with the invention. In one embodiment, the synthetic material is porous.

Alternatively, the sling material may be derived from mammalian tissue(s). The mammalian tissue source may be, for example, human, human cadaveric, or tissue-engineered human tissue. The mammalian tissue may alternatively be derived from an animal source such  
30 as porcine, ovine, bovine, and equine tissue sources.

The sling material may also be made of a combination of mammalian tissue and synthetic material. Such combinations may also include materials that include both synthetic material and animal cells that are treated so as to cross-link the collagen or other commonly antigenic fibers of the animal cells. In one embodiment, at least a portion of the sling 20, which contacts the  
35 patient's tissue, comprises a synthetic material that is substantially smooth.

5           The sling 20 in some configurations is made of a non-wettable material such as a polypropylene, polyethylene, polyester, polytetrafluoroethylene, TYVEK available from DuPont, PA, MYLAR available from DuPont, PA, or co-polymers thereof. Polytetrafluoroethylene, which is suitable for use in accordance with the present invention, is available from DuPont (Wilmington, Delaware, under the trade designation TEFLON).

10           Such non-wettable materials do not take up any liquids, for example, therapeutic agents in solution. To permit therapeutic agents to bond or absorb to these non-wettable material sides, the sling 20 may be treated with a substance that is wettable such as, for example, a wettable coating composition. The wettable coating composition may be a synthetic coating (e.g., polyvinylpyrrolidone or PVP), a natural coating (e.g., collagen) or a physically absorbent material  
15 (e.g., sponge comprising cellulose or open celled polyurethane). The wettable coating composition may be hydrophilic. Suitable hydrophilic coatings may be water soluble and include, for example, such coatings available under the trade designations Hydroplus and Hydropass. Similarly, a hydrophobic coating may be employed on one or more surfaces of the sling 20. Suitable hydrophobic coatings that may be employed in accordance with the invention  
20 include but are not limited to polytetrafluoroethylene, silicon, and Pyrelene.

          Therapeutic agents may also be employed with sling 20. For example, the hydrophilic coating and the therapeutic agent are mixed to form a single coating. Alternatively, the therapeutic agents may be compressed into the material of the sling, rather than being applied as a coating.

25           The therapeutic agents can be, for example, hydrophilic or hydrophobic. Hydrophilic drugs that may be employed in accordance with the invention include oxybutynin chloride, lidocaine, ketorolac, ketorolac tromethamine, which is available under the trade designation Toradol from Roche Pharmaceuticals (Nutley, NJ) and hyoscyamine sulfate which is available under the trade designation CYTOSPAZ from Polymedica (Woburn, MA), for example.  
30           Suitable hydrophobic drugs include but are not limited to ibuprofen, ketoprofen, and diclofenac. The drug can be mixed with the coating and applied with the coating. Where the bonding between the coatings and drugs is weak, the drug that is absorbed will readily release to be delivered to the sides it contacts. Alternatively, a stronger bonding affinity may provide a slower timed release of the drug.

5           Where the coating applied to the surface of the sling 20 has an ionic charge, drugs comprising a complementary charge will bond to the coating when the coating and the drug are exposed to one another. The strength of any bonding will impact how readily the drug is released from the sling 20. Where the ionic bonding between the coating and the drug is weak, the drug will release more readily. In embodiments where rapid drug release is desirable,  
10       covalent bonding between the side coating and the drug should be avoided.

          In general, the therapeutic agent for use in connection with the present invention can be any pharmaceutically acceptable therapeutic agent. Preferred therapeutic agents include anti-inflammatory agents, analgesic agents, local anesthetic agents, antispasmodic agents, and combinations thereof.

15           Anti-inflammatory agents include steroidal and non-steroidal anti-inflammatory agents. Examples of non-steroidal anti-inflammatory drugs, include aminoarylcarboxylic acid derivatives such as enfenamic acid, etofenamate, flufenamic acid, isonixin, meclofenamic acid, mefenamic acid, niflumic acid, talniflumate, terofenamate and tolfenamic acid; arylacetic acid derivatives such as acemetacin, alclofenac, amfenac, bufexamac, cinmetacin, clopirac, diclofenac  
20       sodium, etodolac, felbinac, fenclofenac, fenclozac, fenclozic acid, fentiazac, glucametacin, ibufenac, indomethacin, isofezolac, isoxepac, lonazolac, metiazinic acid, oxametacine, proglumetacin, sulindac, tiaramide, tolmetin and zomepirac; arylbutyric acid derivatives such as bumadizon, butibufen, fenbufen and xenbucin; arylcarboxylic acids such as clidanac, ketorolac and tinoridine; arylpropionic acid derivatives such as alminoprofen, benoxaprofen, bucloxic acid,  
25       carprofen, fenoprofen, flunoxaprofen, flurbiprofen, ibuprofen, ibuproxam, indoprofen, ketoprofen, loxoprofen, miroprofen, naproxen, oxaprozin, piketoprofen, pirprofen, pranoprofen, protizinic acid, suprofen and tiaprofenic acid; pyrazoles such as difenamizole and epirizole; pyrazolones such as apazone, benzpiperylon, feprazone, mofebutazone, morazone, oxyphenbutazone, phenybutazone, pipebuzone, propyphenazone, ramifenazone, suxibuzone and  
30       thiazolinobutazone; salicylic acid derivatives such as acetaminosalol, aspirin, benorylate, bromosaligenin, calcium acetylsalicylate, diflunisal, etersalate, fendosal, gentisic acid, glycol salicylate, imidazole salicylate, lysine acetylsalicylate, mesalamine, morpholine salicylate, 1-naphthyl salicylate, olsalazine, parsalimide, phenyl acetylsalicylate, phenyl salicylate, salacetamide, salicylamine o-acetic acid, salicylsulfuric acid, salsalate and sulfasalazine;  
35       thiazinecarboxamides such as droxicam, isoxicam, piroxicam and tenoxicam; others such as e-

- 5 acetamidocaproic acid, s-adenosylmethionine, 3-amino-4-hydroxybutyric acid, amixetrine, bendazac, benzydamine, bucolome, difenpiramide, ditazol, emorfazone, guaiazulene, nabumetone, nimesulide, orgotein, oxaceprol, paranyline, perisoxal, pifoxime, proquazone, proxazole and tenidap; and pharmaceutically acceptable salts thereof.

Examples of steroidal anti-inflammatory agents (glucocorticoids) include 21-

- 10 acetoxyprefnenolone, aalclometasone, algestone, amicinonide, beclomethasone, betamethasone, budesonide, chloroprednisone, clobetasol, clobetasone, clocortolone, cloprednol, corticosterone, cortisone, cortivazol, deflazacort, desonide, desoximetasone, dexamethasone, diflorasone, diflucortolone, difluprednate, enoxolone, fluazacort, flucloronide, flumehtasone, flunisolide, fluocinolone acetonide, fluocinonide, fluocortin butyl, fluocortolone, fluorometholone,
- 15 fluperolone acetate, fluprednidene acetate, fluprednisolone, flurandrenolide, fluticasone propionate, formocortal, halcinonide, halobetasol priopionate, halometasone, halopredone acetate, hydrocortamate, hydrocortisone, loteprednol etabonate, mazipredone, medrysone, meprednisone, methyolprednisolone, mometasone furoate, paramethasone, prednicarbate, prednisolone, prednisolone 25-diethylaminoacetate, prednisone sodium phosphate, prednisone,
- 20 prednival, prednylidene, rimexolone, tixocortal, triamcinolone, triamcinolone acetonide, triamcinolone benetonide, triamcinolone hexacetonide, and pharmaceutically acceptable salts thereof.

Analgesic agents include narcotic and non-narcotic analgesics. Narcotic analgesic agents include alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide,

- 25 buprenorphine, butorphanol, clonitazene, codeine, codeine methyl bromide, codeine phosphate, codeine sulfate, desomorphine, dextromoramide, dezocine, diampromide, dihydrocodeine, dihydrocodeinone enol acetate, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethlythiambutene, ethylmorphine, etonitazene, fentanyl, hydrocodone, hydromorphone,
- 30 hydroxypethidine, isomethadone, ketobemidone, levorphanol, lofentanil, meperidine, meptazinol, metazocine, methadone hydrochloride, metopon, morphine, myrophine, nalbuphine, narceine, nicomorphine, norlevorphanol, normethadone, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenazocine, pheoperidine, piminodine, piritramide, proheptazine, promedol, properidine, propiram, propoxyphene,
- 35 rumifentanil, sufentanil, tilidine, and pharmaceutically acceptable salts thereof.

5 Non-narcotic analgesics include aceclofenac, acetaminophen, acetaminosalol, acetanilide, acetylsalicylsalicylic acid, alclofenac, alminoprofen, aloxiprin, aluminum bis(acetylsalicylate), aminochlorthenoxazin, 2-amino-4-picoline, aminopropylon, aminopyrine, ammonium salicylate, antolmetin guacil, antipyrine, antipyrine salicylate, antrafenine, apazone, aspirin, benorylate, benoxaprofen, benzpiperylon, benzydamine, bermoprofen, brofenac, p-bromoacetanilide, 5-  
10 bromosalicylic acid acetate, bucetin, bufexamac, bumadizon, butacetin, calcium acetylsalicylate, carbamazepine, carbiphen, carsalam, chloralantipyrine, chlorthenoxazin(e), choline salicylate, cinchophen, ciramadol, clometacin, cropropamide, crotethamide, dexoadrol, difenamizole, diflunisal, dihydroxyaluminum acetylsalicylate, dipyrrocetyl, dipyrone, emorfazone, enfenamic acid, epirizole, etersalate, ethenzamide, ethoxazene, etodolac, felbinac, fenoprofen, floctafenine,  
15 flufenamic acid, fluoresone, flupirtine, fluproquazone, flurbiprofen, fosfosol, gentisic acid, glafenine, ibufenac, imidazole salicylate, indomethacin, indoprofen, isofezolac, isoladol, isonixin, ketoprofen, ketorolac, p-lactophenetide, lefetamine, loxoprofen, lysine acetylsalicylate, magnesium acetylsalicylate, methotrimeprazine, metofoline, mioprofen, morazone, morpholine salicylate, naproxen, nefopam, nifenazone, 5' nitro-2' propoxyacetanilide, parsalimide, perisoxal,  
20 phenacetin, phenazopyridine hydrochloride, phenocoll, phenopyrazone, phenyl acetylsalicylate, phenyl salicylate, phenyramidol, pipebuzone, piperylone, prodilidine, propacetamol, propyphenazone, proxazole, quinine salicylate, ramifenazone, rimazolium metilsulfate, salacetamide, salicin, salicylamide, salicylamide o-acetic acid, salicylsulfuric acid, salsalte, salverine, simetride, sodium salicylate, sulfamipyrine, suprofen, talniflumate, tenoxicam,  
25 terofenamate, tetradrine, tinoridine, tolfenamic acid, tolpronine, tramadol, viminol, xenbucin, zomepirac, and pharmaceutically acceptable salts thereof.

Local anesthetic agents include amucaine, amolanone, amylocaine hydrochloride, benoxinate, benzocaine, betoxycaine, biphenamine, bupivacaine, butacaine, butaben, butanilicaine, butethamine, butoxycaine, carticaine, chloroprocaine hydrochloride, cocaethylene,  
30 cocaine, cyclomethycaine, dibucaine hydrochloride, dimethisoquin, dimethocaine, diperadon hydrochloride, dyclonine, ecgonidine, ecgonine, ethyl chloride, beta-eucaine, euprocin, fenalcomine, fomocaine, hexylcaine hydrochloride, hydroxytetracaine, isobutyl p-aminobenzoate, leucinocaine mesylate, levoadrol, lidocaine, mepivacaine, meprylcaine, metabutoxycaine, methyl chloride, myrtecaine, naepaine, octacaine, orthocaine, oxethazaine,  
35 parethoxycaine, phenacaine hydrochloride, phenol, piperocaine, piridocaine, polidocanol,



5 pramoxine, prilocaine, procaine, propanocaine, proparacaine, propipocaine, propoxycaine hydrochloride, pseudococaine, pyrrocaine, ropavacaine, salicyl alcohol, tetracaine hydrochloride, tolycaine, trimecaine, zolamine, and pharmaceutically acceptable salts thereof.

Antispasmodic agents include alibendol, ambucetamide, aminopromazine, apoatropine, bevonium methyl sulfate, bietamiverine, butaverine, butropium bromide, n-  
10 butylscopolammonium bromide, caroverine, cimetropium bromide, cinnamedrine, clebopride, coniine hydrobromide, coniine hydrochloride, cyclonium iodide, difemerine, diisopromine, dioxaphetyl butyrate, diponium bromide, drofenine, emepromium bromide, ethaverine, feclemine, fenalamide, fenoverine, fempiprane, fempiverinium bromide, fentonium bromide, flavoxate, flopropione, gluconic acid, guaiactamine, hydramitrazine, hymecromone, leiopyrrole,  
15 mebeverine, moxaverine, nafiverine, octamylamine, octaverine, oxybutynin chloride, pentapiperide, phenamacide hydrochloride, phloroglucinol, pinaverium bromide, piperilate, pipoxolan hydrochloride, pramiverin, prifinium bromide, properidine, propivane, propyromazine, prozapine, racefemine, rociverine, spasmolytol, stilonium iodide, sultroponium, tiemonium iodide, tiquizium bromide, tiropamide, trepibutone, tricromyl, trifolium, trimebutine,  
20 n,n-1 trimethyl-3,3-diphenyl-propylamine, tropenzile, trospium chloride, xenytrypium bromide, and pharmaceutically acceptable salts thereof.

Two particularly preferred therapeutic agents for the practice of the present invention are (a) ketorolac and pharmaceutically acceptable salts thereof (e.g., the tromethamine salt thereof, sold under the commercial name Toradol®) and (b) 4-diethylamino-2-  
25 butynylphenylcyclohexylglycolate and pharmaceutically acceptable salts thereof (e.g., 4-diethylamino-2-butynylphenylcyclohexylglycolate hydrochloride, also known as oxybutynin chloride, sold under the commercial name Ditropan®).

The amount of the therapeutic agent present in the polymeric matrix is an amount effective to reduce the pain or discomfort associated with the medical device. Typically, the  
30 therapeutic agent is present in a polymeric matrix in a range from about 0.1% to about 30% by weight of the polymeric matrix (including 0.1%, 0.2%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30% and ranges between any two of these points, for instance, 0.1-10%, 10-20% and 20-30%, etc.). Where the oxybutynin chloride and ketorolac tromethamine  
35 are used a range of 2-20% is typical, more typically 5-15%.

5           Alternatively, other therapeutic agents as known to those in the field as useful to enhance the efficacy of the sling or reduce adverse reactions to the sling, for example, are contemplated with respect to the invention.

          An exemplary method of making a sling 20 includes constructing a length of material having a first portion that is relatively stretchable and a second portion that is substantially non-  
10   stretchable. In one embodiment, the sling 20 is manufactured having a member extending longitudinally along the second portion of the sling 20.

          The sling 20 disclosed herein can be used to treat female urinary stress incontinence. Methods of sling delivery and implantation include but are not limited to tranvaginal, transabdominal, and transobturator procedures. In one embodiment, a sling 20 having a first and  
15   a second edge structurally strengthened is placed inside the body of a patient such that the axis of the sling 20 that is perpendicular to the long axis of the sling parallels a portion of the mid-urethra. The sling 20 thereby provides a urethral platform limiting endopelvic fascia drop while providing compression to the urethral sphincter.

          Variations, modifications, and other implementations of what is described herein will  
20   occur to those of ordinary skill without departing from the spirit and the scope of the invention. Accordingly, the invention is not to be limited only to the preceding illustrative description.

          What is claimed is:

Claims

- 1           1.     A sling comprising:
  - 2           a first portion, a second portion, and an intermediate portion located longitudinally
  - 3       between the first and second portions;
  - 4           a first elongated member extending longitudinally along the first portion;
  - 5           a second elongated member extending longitudinally along the second portion; and
  - 6           the first and second elongated members being separated by the intermediate portion of
  - 7       the sling.
- 1           2.     The sling according to claim 1, wherein the first and second elongated members comprise
- 2       a substantially rigid material.
- 1           3.     The sling according to claim 1, wherein at least one of the first and second elongated
- 2       members is integral with the portions of the sling along which the members extend.
- 1           4.     The sling according to claim 1, wherein the intermediate portion is about 1 cm to about
- 2       15 cm in length.
- 1           5.     The sling according to claim 1, wherein intermediate portion is about 1 cm to about 7 cm
- 2       in length.
- 1           6.     The sling according to claim 1, further comprising a tensioning device located in the
- 2       intermediate portion of the sling.
- 1           7.     The sling according to claim 6, wherein the tensioning device comprises a looped thread.
- 1           8.     The sling according to claim 7, wherein the thread is attached to one or both of the first
- 2       and second elongated members.
- 1           9.     The sling according to claim 1, wherein the sling is non-perforated.
- 1           10.    The sling according to claim 1, wherein the sling is a mesh.
- 1           11.    A sling comprising a first edge structurally strengthened to increase sling rigidity.
- 1           12.    The sling according to claim 11, comprising a second edge structurally strengthened to
- 2       increase sling rigidity.
- 1           13.    The sling according to claim 12, wherein at least a portion of the first edge is detanged.
- 1           14.    The sling according to claim 13, wherein at least a portion of the second edge is
- 2       detanged.

1 15. The sling according to claim 14, wherein at least a portion of the first edge and the  
2 second edge is detanged.

1 16. A method of making a sling for implantation at an anatomical site in a patient, the  
2 method comprising:

3       securing to the sling a first elongated member extending longitudinally along a first  
4 portion of the sling; and

5       securing to the sling a second elongated member extending longitudinally along a second  
6 portion of the sling, the first and second portions being separated by an intermediate portion.

1 17. The method according to claim 16, wherein the first and second elongated members  
2 comprise a substantially rigid material.

1 18. The method according to claim 16, wherein the intermediate portion is about 1 cm to  
2 about 15 cm in length.

1 19. The method according to claim 16, wherein intermediate portion is about 1 cm to about 7  
2 cm in length.

1 20. The method according to claim 16, wherein the sling is perforated.

1 21. The method according to claim 16, wherein sling is a mesh.

1 22. The method according to claim 16, wherein the sling comprises a synthetic material.

1 23. The method according to claim 16, wherein the sling comprises a mammalian tissue.

1 24. The method according to claim 16, wherein the sling comprises a combination of a  
2 synthetic material and a mammalian tissue.

1 25. A method of making a sling, the method comprising the steps of:

2       providing a sling having first and second edges, and

3       treating at least a portion of at least one of the first and second edges to increase  
4 structural rigidity of the sling.

1 26. The method of claim 25, wherein the treating comprises smoothing the portion of the at  
2 least one of the first and second edges.

1 27. The method of claim 26, wherein the smoothing comprises melting the portion of the at  
2 least one of the first and second edges.

1 28. The method of claim 27, wherein the melting is performed with a heating element.

- 1 29. The method of claim 25, wherein the at least one of the first or second edges comprises  
2 tangs and treating at least the portion comprising smoothing the portion to substantially remove  
3 the tangs.
- 1 30. The method of claim 25, wherein the sling is formed from a non-perforated material.
- 1 31. The method of claim 25, wherein the sling is formed from a perforated material.

1/6




FIG. 1




FIG. 2




FIG. 3

3/6




FIG. 4



4/6




FIG. 5

5/6




FIG. 6

6/6




FIG. 7

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 03/25452

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61F2/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	US 6 110 101 A (RYDELL MARK A ET AL) 29 August 2000 (2000-08-29)  figure 7 column 3, line 15 -column 4, line 6	1-10, 16-24 11-15, 25-31
Y	WO 02/071931 A (SCIMED LIFE SYSTEMS INC) 19 September 2002 (2002-09-19) page 7, line 26 -page 8, line 2 page 7, line 3 - line 10	11-15, 25-31
X A	WO 98/35632 A (BOSTON SCIENT IRELAND LTD ;GELLMAN BARRY N (US); MARTIN WILLIAM (U) 20 August 1998 (1998-08-20)  figures 9A,9B	1  2-31

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the International filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the International filing date but later than the priority date claimed

\*T\* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*&amp;\* document member of the same patent family

Date of the actual completion of the international search

6 April 2004

Date of mailing of the international search report

16/04/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Franz, V

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/25452

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	US 2003/065402 A1 (ANDERSON KIMBERLY A ET AL) 3 April 2003 (2003-04-03)  figure 6 paragraph '0081! -----	1  2-31
X A	US 2002/099258 A1 (ANDERSON KIMBERLY A ET AL) 25 July 2002 (2002-07-25)  figure 9B paragraphs '0114!, '0126! -----	1  2-31
X A	WO 00/74633 A (ETHICON INC) 14 December 2000 (2000-12-14)  figure 5A -----	1  2-31
X A	DE 202 04 669 U (AESCULAP AG & CO KG) 7 August 2003 (2003-08-07)  page 2, line 18 - line 22 -----	1  2-31

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/25452

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6110101	A	29-08-2000	US 6042536 A EP 1065992 A1 WO 0009039 A1 TW 450800 B	28-03-2000 10-01-2001 24-02-2000 21-08-2001
WO 02071931	A	19-09-2002	CA 2439212 A1 CA 2440153 A1 EP 1365688 A2 EP 1365679 A1 WO 02071953 A2 WO 02071931 A1 US 2002138025 A1 US 2002156487 A1 US 2002151909 A1 US 2002156488 A1 US 2002156489 A1 US 2002151910 A1 US 2003009181 A1	19-09-2002 19-09-2002 03-12-2003 03-12-2003 19-09-2002 19-09-2002 26-09-2002 24-10-2002 17-10-2002 24-10-2002 24-10-2002 17-10-2002 09-01-2003
WO 9835632	A	20-08-1998	AU 6329598 A CA 2280814 A1 DE 69808614 D1 DE 69808614 T2 EP 0983033 A1 JP 2001511685 T US 6042534 A WO 9835632 A1	08-09-1998 20-08-1998 14-11-2002 18-06-2003 08-03-2000 14-08-2001 28-03-2000 20-08-1998
US 2003065402	A1	03-04-2003	NONE	
US 2002099258	A1	25-07-2002	BR 0116812 A CA 2403687 A1 CA 2404459 A1 CA 2434461 A1 EP 1353597 A1 EP 1353601 A1 EP 1353599 A2 US 2002147382 A1 WO 02058562 A1 WO 02062237 A1 WO 02058564 A2 US 2003045774 A1 US 2003050530 A1 US 2004039453 A1 US 2004015057 A1 US 2002151762 A1 CA 2434027 A1 CA 2434463 A1 EP 1353600 A2 EP 1353598 A1 WO 02058565 A2 WO 02058563 A1 US 2003130670 A1 US 2004015048 A1 US 2002099259 A1 US 2002107430 A1	27-01-2004 01-08-2002 15-08-2002 01-08-2002 22-10-2003 22-10-2003 22-10-2003 10-10-2002 01-08-2002 15-08-2002 01-08-2002 06-03-2003 13-03-2003 26-02-2004 22-01-2004 17-10-2002 01-08-2002 01-08-2002 22-10-2003 22-10-2003 01-08-2002 01-08-2002 10-07-2003 22-01-2004 25-07-2002 08-08-2002
WO 0074633	A	14-12-2000	AU 4710500 A	28-12-2000

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/25452

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0074633	A	AU 5315300 A	28-12-2000
		AU 769863 B2	05-02-2004
		AU 5465900 A	28-12-2000
		BR 0011726 A	05-08-2003
		CA 2376278 A1	14-12-2000
		CA 2376281 A1	14-12-2000
		CA 2376282 A1	14-12-2000
		CN 1409625 T	09-04-2003
		CN 1433288 T	30-07-2003
		EP 1200011 A1	02-05-2002
		EP 1194091 A1	10-04-2002
		JP 2003523786 T	12-08-2003
		JP 2003501144 T	14-01-2003
		JP 2004500152 T	08-01-2004
		WO 0074594 A1	14-12-2000
		WO 0074613 A1	14-12-2000
		WO 0074633 A2	14-12-2000
		US 2002188169 A1	12-12-2002
		US 2003023138 A1	30-01-2003
		US 2003149440 A1	07-08-2003
		US 6273852 B1	14-08-2001
		US 6475139 B1	05-11-2002
		US 2002077526 A1	20-06-2002
		US 2001049467 A1	06-12-2001
DE 20204669	U	DE 20204669 U1	07-08-2003
		WO 03013392 A1	20-02-2003